<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02988778</url>
  </required_header>
  <id_info>
    <org_study_id>EF149</org_study_id>
    <nct_id>NCT02988778</nct_id>
  </id_info>
  <brief_title>Clinical Study, Non Inferiority Between Noex® 50µg Versus Busonid® 50µg in Treatment of Allergic Rhinitis</brief_title>
  <acronym>RINEX50</acronym>
  <official_title>Phase III, Multicenter, Randomized, Simple-blinded, Parallel Groups to Evaluate Non Inferiority of Noex® 50µg Versus Busonid® 50µg in Treatment of Allergic Persistent Rhinitis Moderate to Severe</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eurofarma Laboratorios S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eurofarma Laboratorios S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate non inferiority of Eurofarma budesonide nasal spray x referral
      Astrazeneca budesonide. Half patients will receive Eurofarma medication and half patients
      will receive Astrazeneca medication. There is no placebo group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Budesonide is a medicine already very used and registered about 20 years. Eurofarma has the
      intention to collect more data about safety and efficacy and present them to local authority.

      This study was draw to treat patients with persistent rhinitis moderate to severe in sites
      located locally in Brazil.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2018</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Demonstrate non inferiority of Noex using the questionnaire Nasal Index Score (NIS)</measure>
    <time_frame>28 days</time_frame>
    <description>Using the questionnaire Nasal Index Score (NIS)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Rhinitis, Allergic, Perennial</condition>
  <arm_group>
    <arm_group_label>Budesonid 50mcg (Noex)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budesonid 50mcg (Noex), 2 atomizations in each nostril by the morning and during the night, total of 400 mcg per day.
Treatment of 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonid 50mcg (Busonid)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Budesonid 50mcg (Busonid), 2 atomizations in each nostril by the morning and during the night, total of 400 mcg per day.
Treatment of 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonid 50mcg (Noex)</intervention_name>
    <description>Suspention to nasal use, 2 atomization in each nostril during the morning and at night.</description>
    <arm_group_label>Budesonid 50mcg (Noex)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonid 50mcg (Busonid)</intervention_name>
    <description>Suspention to nasal use, 2 atomization in each nostril during the morning and at night.</description>
    <arm_group_label>Budesonid 50mcg (Busonid)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 12

          2. History of allergic persistent rhinitis moderate to severe at least 2 years

          3. Proved allergic using PRICK or RAST test

          4. Nasal symptoms (NIS) &gt; 3 and nasal obstruction &gt;1

          5. Indication of nasal corticosteroids use

          6. Washout of nasal corticosteroids for 14 days

          7. ICF

        Exclusion Criteria:

          1. Other types of rhinitis

          2. Asthma non controlled

          3. Use of oral/injectable corticoids 30 days before screening

          4. patients not eligible to complete diaries

          5. patients with allergy to any substance of medicines

          6. non controlled disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mauro Acir Crippa Junior, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allergisa Pesquisa Dermato-Cosmetica LTDA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandra Dumont</last_name>
    <phone>+5519 3789-8600</phone>
    <email>alexandra@grupoinvestiga.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alexandra Dumont</name>
      <address>
        <city>Campinas</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2016</study_first_submitted>
  <study_first_submitted_qc>December 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2016</study_first_posted>
  <last_update_submitted>September 14, 2017</last_update_submitted>
  <last_update_submitted_qc>September 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Undecided, but could be shared upon investigator's request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

